![]() ![]() CUIIHNPMMCYAMK-UHFFFAOYSA-N methyl 1,2,3-benzothiadiazole-7-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1SN=N2 CUIIHNPMMCYAMK-UHFFFAOYSA-N 0.000 claims description 7.COAIOOWBEPAOFY-UHFFFAOYSA-N 1,2,3-benzothiadiazole-7-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1SN=N2 COAIOOWBEPAOFY-UHFFFAOYSA-N 0.000 claims description 7.-1 isonicotinic acid compound Chemical class 0.000 claims description 8.FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 claims description 10.YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 48.230000014493 regulation of gene expression Effects 0.000 claims abstract description 6.230000001105 regulatory Effects 0.000 claims abstract description 66.229920001405 Coding region Polymers 0.000 claims abstract description 74.108091006028 chimera Proteins 0.000 claims abstract description 106.239000000126 substance Substances 0.000 claims abstract description 129.230000014509 gene expression Effects 0.000 claims abstract description 129.210000001519 tissues Anatomy 0.000 claims abstract description 133.229920003013 deoxyribonucleic acid Polymers 0.000 claims abstract description 228.230000001775 anti-pathogenic Effects 0.000 title abstract description 11.229920001850 Nucleic acid sequence Polymers 0.000 title abstract description 286.Assignors: NOVARTIS FINANCE CORPORATION Anticipated expiration legal-status Critical Status Expired - Fee Related legal-status Critical Current Links Application granted granted Critical Publication of US5804693A publication Critical patent/US5804693A/en Assigned to SYNGENTA INVESTMENT CORPORATION reassignment SYNGENTA INVESTMENT CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). BERNARDUS T., WARD, ERIC R., RYALS, JOHN A. Assignors: UKNES, SCOTT J., GAFFNEY, THOMAS D., KESSMANN, HELMUT, FRIEDRICH, LESLIE B., VERNOOIJ, B. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US16566788A external-priority Application filed by Novartis Finance Corp filed Critical Novartis Finance Corp Priority to US08/454,876 priority Critical patent/US5804693A/en Assigned to NOVARTIS FINANCE CORPORATION reassignment NOVARTIS FINANCE CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Original Assignee Novartis Finance Corp Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Vernooij Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired - Fee Related Application number US08/454,876 Inventor Thomas D. Google Patents Chemically regulatable and anti-pathogenic DNA sequences and uses thereofÄownload PDF Info Publication number US5804693A US5804693A US08/454,876 US45487695A US5804693A US 5804693 A US5804693 A US 5804693A US 45487695 A US45487695 A US 45487695A US 5804693 A US5804693 A US 5804693A Authority US United States Prior art keywords plant gene sequence dna plasmid Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US5804693A - Chemically regulatable and anti-pathogenic DNA sequences and uses thereof US5804693A - Chemically regulatable and anti-pathogenic DNA sequences and uses thereof ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |